SCHEMBL4187591

SCHEMBL4187591

Fc1ccc(CNc2cncc(-c3cccnc3)c2)cc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.59
MAPT P10636 1/20 0.59
PABPC1 P11940 1/20 0.59
KMT2A Q03164 1/20 0.59
GPR55 Q9Y2T6 1/20 0.48
PDE4B Q07343 3/20 0.47
DYRK1A Q13627 3/20 0.47
CLK1 P49759 2/20 0.47
RAB9A P51151 1/20 0.46
METAP2 P50579 1/20 0.45
EPHX2 P34913 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
HDAC1 Q13547 1/20 0.44
FYN P06241 1/20 0.44
BACE1 P56817 1/20 0.43
VNN1 O95497 1/20 0.43
LTA4H P09960 1/20 0.42
KCNH2 Q12809 1/20 0.42
HASPIN Q8TF76 1/20 0.42
DYRK1B Q9Y463 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4928970 0.89 DYRK1A (0.48) MEN1MAPTPABPC1KMT2AGPR55
SCHEMBL4149001 0.86 MEN1 (0.48) MEN1MAPTPABPC1KMT2APDE4B
SCHEMBL4193131 0.85 MEN1 (0.46) MEN1MAPTPABPC1KMT2APDE4B
SCHEMBL4189096 0.84 FYN (0.64) MEN1MAPTPABPC1KMT2APDE4B
SCHEMBL4180572 0.83 LTA4H (0.61) MEN1MAPTPABPC1KMT2ARAB9A
SCHEMBL4193176 0.82 DYRK1A (0.60) MEN1MAPTKMT2APDE4BDYRK1A
SCHEMBL4140694 0.82 FYN (0.46) MEN1MAPTPABPC1KMT2ARAB9A
SCHEMBL4191983 0.82 MEN1 (0.43) MEN1MAPTPABPC1KMT2ADYRK1A
SCHEMBL4182323 0.80 CLK1 (0.54) MEN1MAPTPABPC1KMT2APDE4B
SCHEMBL4189080 0.80 TDP2 (0.55) MEN1MAPTPABPC1KMT2APRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 MEN1 2363/4885MAPT 3192/4885PABPC1 4036/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 MEN1 2363/4885MAPT 3192/4885PABPC1 4036/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 MEN1 2363/4885MAPT 3192/4885PABPC1 4036/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA MEN1 826/4885MAPT 23/4885PABPC1 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.